Orungal in solution is used in the treatment of oral cavity and esophageal candidiasis in patients who suffer from immunodeficiency and HIV patients. The drug is used in the treatment of systemic fungal infections in patients who have been diagnosed with malignant blood diseases, as well as in patients who have undergone a bone marrow transplant, with an increased risk of neutropenia.
Orungal composition and form of release
Manufactured in oral solution. The active substance of the drug is itraconazole.
Indications Orungal in solution is used in the treatment of oral cavity and esophageal candidiasis in patients who suffer from immunodeficiency and HIV patients. The drug is used in the treatment of systemic fungal infections in patients who have been diagnosed with malignant blood diseases, as well as in patients who have undergone a bone marrow transplant, with an increased risk of neutropenia.
An absolute contraindication to use is hypersensitivity to its components. In addition to this, the drug cannot be used in joint therapy with ergot alkaloids, midazolam, triazolam, as well as drugs metabolized with the participation of the CYP3A4 enzyme and capable of increasing the QT interval. It is also recommended to abandon the joint use of the drug with HMG-CoA reductase inhibitors, which are metabolized with the participation of the CYP3A4 enzyme.
Relative contraindications to the appointment of Orungal are childhood, chronic heart failure, cirrhosis of the liver, chronic renal failure, hypersensitivity to drug components.
Application during pregnancy and lactation
The use of lactating and pregnant women in therapy is justified only if the patient suffers from systemic mycoses that threaten her life.
Method of administration and dosage
When using Orungal in the form of an oral solution, the drug should be taken orally on an empty stomach. When using the product, you must put it in your mouth and rinse the mucous membrane with it and only then swallow it.
When treating candidiasis of the oral mucosa or esophagus, take in one or two doses of 200 mg per day, the duration of therapy is 7 days, if necessary, the duration of treatment can be doubled. To prevent the development of systemic fungal infections, the patient is prescribed 5 mg per kg of body twice a day. The use of the drug should be started 7 days before the start of cytostatic therapy or 7 days after bone marrow transplantation. Treatment continues until the number of neutrophils is restored.
No cases of drug overdose have been recorded. When taking the drug in high doses, the patient is prescribed gastric lavage and the intake of enterosorbents.
When taking the drug, patients develop anorexia, epigastric pain, dyspepsia, hepatitis, toxic liver damage, headaches, dizziness, peripheral neuropathy, angioedema, allergic reactions, alopecia, photosensitivity, dysmenorrhea, pulmonary edema.
Storage conditions and periods
Orungal is stored in places protected from the penetration of children at a temperature of no more than 30 degrees. The drug should be stored no more than 3 years from the date of manufacture.